Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralph A Defronzo

Showing results (1-10 of 313) with videos related to

Pageof 32
Sort By:
The American Journal of Medicine|March 9, 2010
Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is goingRalph A DeFronzo
The Medical Clinics of North America|August 17, 2004
Pathogenesis of type 2 diabetes mellitusRalph A DeFronzo
Diabetes, Obesity & Metabolism|April 23, 2017
Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitorRalph A DeFronzo
Expert Review of Endocrinology & Metabolism|February 16, 2019
Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitusCurtis Triplitt, Ralph A DeFronzo
European Heart Journal|June 12, 2015
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetesEle Ferrannini, Ralph A DeFronzo
Carcinogenesis|November 7, 2017
A novel experimental model for human mixed acinar-ductal pancreatic cancerBruno Doiron, Ralph A DeFronzo
Kidney International|June 16, 2026
Role of the Kidney in Glucose Homeostasis: The Basis for Pharmacotherapy and Prevention of Cardio-Renal Complications in DiabetesEugenio Cersosimo, Ralph A DeFronzo
Diabetes/Metabolism Research and Reviews|March 1, 2006
Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseasesEugenio Cersosimo, Ralph A DeFronzo
Diabetes Care|June 27, 2013
Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: The time has come for GLP-1 receptor agonists!Stanley Schwartz, Ralph A DeFronzo
Current Diabetes Reports|February 12, 2014
The use of non-insulin anti-diabetic agents to improve glycemia without hypoglycemia in the hospital setting: focus on incretinsStanley Schwartz, Ralph A DeFronzo
Pageof 32

Showing results (1-10 of 313) with videos related to

Sort By:
Pageof 32
The American Journal of Medicine|March 9, 2010
Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is goingRalph A DeFronzo
The Medical Clinics of North America|August 17, 2004
Pathogenesis of type 2 diabetes mellitusRalph A DeFronzo
Diabetes, Obesity & Metabolism|April 23, 2017
Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitorRalph A DeFronzo
Expert Review of Endocrinology & Metabolism|February 16, 2019
Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitusCurtis Triplitt, Ralph A DeFronzo
European Heart Journal|June 12, 2015
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetesEle Ferrannini, Ralph A DeFronzo
Carcinogenesis|November 7, 2017
A novel experimental model for human mixed acinar-ductal pancreatic cancerBruno Doiron, Ralph A DeFronzo
Kidney International|June 16, 2026
Role of the Kidney in Glucose Homeostasis: The Basis for Pharmacotherapy and Prevention of Cardio-Renal Complications in DiabetesEugenio Cersosimo, Ralph A DeFronzo
Diabetes/Metabolism Research and Reviews|March 1, 2006
Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseasesEugenio Cersosimo, Ralph A DeFronzo
Diabetes Care|June 27, 2013
Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: The time has come for GLP-1 receptor agonists!Stanley Schwartz, Ralph A DeFronzo
Current Diabetes Reports|February 12, 2014
The use of non-insulin anti-diabetic agents to improve glycemia without hypoglycemia in the hospital setting: focus on incretinsStanley Schwartz, Ralph A DeFronzo
Pageof 32